Carisma Therapeutics, Inc. (CARM)

Carisma Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2.78	17.91	77.61	24.19	28.55	51.79
Short-Term Investments	-	0.93	0.89	27.8	-	-
Cash & Short-Term Investments	2.78	18.83	78.5	52	28.55	51.79
Cash Growth	-90.13%	-76.01%	50.97%	82.12%	-44.87%	-
Receivables	1.64	2.86	-	-	-	-
Prepaid Expenses	1.41	0.34	0.4	2.6	1.24	1.28
Other Current Assets	0.05	1.79	1.57	-	-	-
Total Current Assets	5.87	23.83	80.47	54.59	29.79	53.07
Property, Plant & Equipment	0.68	6.43	8.94	13.45	5.66	5.19
Long-Term Deferred Charges	-	0.21	0.15	4.11	-	-
Other Long-Term Assets	-	-	-	-	-	0.21
Total Assets	6.55	30.46	89.55	72.15	35.45	58.46

Liabilities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	5.57	2.08	3.93	1.73	2.32	3.29
Accrued Expenses	1.09	7.45	7.66	10.36	4.47	1.57
Current Portion of Leases	0.15	1.74	1.94	4.6	0.9	0.81
Current Unearned Revenue	-	3.73	1.41	2.46	-	-
Other Current Liabilities	-	1.06	0.97	0.52	-	-
Total Current Liabilities	6.81	16.06	15.91	19.67	7.69	5.68
Long-Term Debt	-	-	-	33.72	-	-
Long-Term Leases	0.61	0.74	1.19	1.85	1.73	2.63
Long-Term Unearned Revenue	-	41.25	45	45	-	-
Other Long-Term Liabilities	-	0.32	0.93	6.78	-	-
Total Liabilities	7.42	58.37	63.02	107.02	9.43	8.31

Shareholders' Equity

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0.04	0.04	0.04	0	-	-
Additional Paid-In Capital	278.99	277.63	271.59	1.2	0.82	0.34
Retained Earnings	-279.9	-305.58	-245.1	-158.22	-97	-56.21
Comprehensive Income & Other	-	-	-	-0.04	-	-
Total Common Equity	-0.87	-27.91	26.53	-157.07	-96.18	-55.87
Minority Interest	-	-	-	14.4	14.4	14.4
Shareholders' Equity	-0.87	-27.91	26.53	-34.86	26.02	50.15
Total Liabilities & Equity	6.55	30.46	89.55	72.15	35.45	58.46

Additional Metrics

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	0.76	2.48	3.12	40.16	2.63	3.45
Net Cash (Debt)	2.02	16.35	75.37	11.83	25.92	48.34
Net Cash Growth	-91.88%	-78.30%	537.03%	-54.35%	-46.38%	-
Net Cash Per Share	0.05	0.39	2.25	5.56	23.91	45.46
Filing Date Shares Outstanding	41.85	41.79	41.54	1.17	11.09	1.06
Total Common Shares Outstanding	41.79	41.75	40.61	1.17	1.08	1.06
Working Capital	-0.94	7.77	64.56	34.92	22.1	47.39
Book Value Per Share	-0.02	-0.67	0.65	-134.52	-88.72	-52.55
Tangible Book Value	-0.87	-27.91	26.53	-157.07	-96.18	-55.87
Tangible Book Value Per Share	-0.02	-0.67	0.65	-134.52	-88.72	-52.55
Machinery	-	4.82	5.36	7.63	3.96	2.09
Construction In Progress	-	-	0.01	0.01	0.01	-
Leasehold Improvements	-	0.34	0.34	0.34	0.32	0.32

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 26, 2026

Data Sources Report a data error